New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

[Guest guest]

BlankNew and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic

Leukemia.

L ti, L De Padua, G D'Arena, B Vannata, I Innocenti, M Tarnani, S Deaglio,

S Sica, DG Efremov, and G Leone

Mini Rev Med Chem, May 11, 2011; .

Hematology Department, Catholic University of 'Sacred Hearth', Largo Agostino

Gemelli, 00168 Rome, Italy. l.laurenti@... .

Over the last few years, several new agents have been under evaluation in

preclinical studies and clinical trials, showing promise in treating chronic

lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs)

such as rituximab and alemtuzumab have changed the natural course of the

disease. Nowadays there are several new promising monoclonal antibodies under

investigation against the CD20, CD23, CD37 and CD40 molecules. Application of

newer monoclonal antibodies represents an area of ongoing clinical research in

CLL.

PMID: 21561405